Open AccessInfluence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls
Author(s) -
Juris J. Meier,
Michael A. Nauck,
Bartholomaeus Kask,
Jens J. Holst,
Carolyn F. Deacon,
Wolfgang E. Schmidt,
Baptist Gallwitz
Publication year - 2006
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v12.i12.1874
Subject(s) - gastric inhibitory polypeptide , medicine , endocrinology , pentagastrin , gastric acid , incretin , placebo , gastrointestinal hormone , type 2 diabetes , diabetes mellitus , hormone , peptide hormone , stomach , glucagon , alternative medicine , pathology
Gastric inhibitory polypeptide is secreted from intestinal K-cells in response to nutrient ingestion and acts as an incretin hormone in human physiology. While animal experiments suggested a role for GIP as an inhibitor of gastric secretion, the GIP effects on gastric acid output in humans are still controversial.